Published in J Biol Chem on April 19, 2010
Exposure of R169 controls protein C activation and autoactivation. Blood (2012) 1.52
Conformational selection or induced fit? A critical appraisal of the kinetic mechanism. Biochemistry (2012) 1.39
Crystallographic and kinetic evidence of allostery in a trypsin-like protease. Biochemistry (2011) 0.98
Crystal structures of prethrombin-2 reveal alternative conformations under identical solution conditions and the mechanism of zymogen activation. Biochemistry (2011) 0.97
Autosomal-recessive posterior microphthalmos is caused by mutations in PRSS56, a gene encoding a trypsin-like serine protease. Am J Hum Genet (2011) 0.96
Autoactivation of thrombin precursors. J Biol Chem (2013) 0.92
Redesigning allosteric activation in an enzyme. Proc Natl Acad Sci U S A (2011) 0.82
Expansion of protein farnesyltransferase specificity using "tunable" active site interactions: development of bioengineered prenylation pathways. J Biol Chem (2012) 0.79
WEDGE: an anticoagulant thrombin mutant produced by autoactivation. J Thromb Haemost (2014) 0.77
Thrombomodulin Binding Selects the Catalytically Active Form of Thrombin. Biochemistry (2015) 0.77
Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants. Biochim Biophys Acta (2011) 0.77
Transcriptome analysis revealed unique genes as targets for the anti-inflammatory action of activated protein C in human macrophages. PLoS One (2010) 0.77
Thrombin Cleavage of Plasmodium falciparum Erythrocyte Membrane Protein 1 Inhibits Cytoadherence. MBio (2016) 0.76
Salmon-derived thrombin inhibits development of chronic pain through an endothelial barrier protective mechanism dependent on APC. Biomaterials (2015) 0.76
Rational Design of Protein C Activators. Sci Rep (2017) 0.75
Switching cation-binding loops paves the way for redesigning allosteric activation. Proc Natl Acad Sci U S A (2011) 0.75
Screening Cleavage of Factor XIII V34X Activation Peptides by Thrombin Mutants: A Strategy for Controlling Fibrin Architecture. Biochim Biophys Acta (2017) 0.75
Induced fit is a special case of conformational selection. Biochemistry (2017) 0.75
On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun (1967) 18.32
Thrombin signalling and protease-activated receptors. Nature (2000) 9.27
Serine protease mechanism and specificity. Chem Rev (2002) 5.46
Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science (2002) 5.35
Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost (2005) 4.64
Structural basis of substrate specificity in the serine proteases. Protein Sci (1995) 4.22
Additivity of mutational effects in proteins. Biochemistry (1990) 4.05
Serine peptidases: classification, structure and function. Cell Mol Life Sci (2008) 2.17
The search for new cardiovascular biomarkers. Nature (2008) 2.14
Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem (1997) 2.05
Conversion of thrombin into an anticoagulant by protein engineering. Nature (1995) 1.98
Thrombin and platelet activation. Chest (2003) 1.89
Thrombin. Mol Aspects Med (2008) 1.80
Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist. Arterioscler Thromb Vasc Biol (2007) 1.80
Rational engineering of activity and specificity in a serine protease. Nat Biotechnol (1997) 1.79
Molecular dissection of Na+ binding to thrombin. J Biol Chem (2004) 1.72
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem (2007) 1.67
Exosites in the substrate specificity of blood coagulation reactions. J Thromb Haemost (2007) 1.61
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem (2006) 1.58
The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur J Biochem (1992) 1.53
Glu-192----Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin. Proc Natl Acad Sci U S A (1991) 1.46
Thrombin. Ann N Y Acad Sci (1986) 1.44
Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol (2002) 1.38
Functional mapping of the surface residues of human thrombin. J Biol Chem (1995) 1.38
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood (2009) 1.36
Highly active and selective endopeptidases with programmed substrate specificities. Nat Chem Biol (2008) 1.33
Molecular mapping of thrombin-receptor interactions. Proteins (2001) 1.32
Rational design of a potent anticoagulant thrombin. J Biol Chem (2000) 1.32
Structural identification of the pathway of long-range communication in an allosteric enzyme. Proc Natl Acad Sci U S A (2008) 1.31
Rapid kinetics of Na+ binding to thrombin. J Biol Chem (2006) 1.29
Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc Natl Acad Sci U S A (2007) 1.23
The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem (2002) 1.19
Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry (1996) 1.17
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood (2007) 1.12
Crystal structure of thrombin in a self-inhibited conformation. J Biol Chem (2006) 1.11
Unexpected crucial role of residue 225 in serine proteases. Proc Natl Acad Sci U S A (1999) 1.11
The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. J Biol Chem (2004) 1.10
Thrombomodulin changes the molecular surface of interaction and the rate of complex formation between thrombin and protein C. J Biol Chem (2004) 1.08
Redesigning the monovalent cation specificity of an enzyme. Proc Natl Acad Sci U S A (2003) 1.05
Structure and interaction modes of thrombin. Blood Cells Mol Dis (2006) 1.04
Blood coagulation. The thrombin paradox. Nature (1995) 1.02
Release of fibrinopeptides by the slow and fast forms of thrombin. Biochemistry (1996) 1.00
Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR-1 or protein C. Biochemistry (2000) 0.99
Mutant N143P reveals how Na+ activates thrombin. J Biol Chem (2009) 0.97
Important role of the cys-191 cys-220 disulfide bond in thrombin function and allostery. J Biol Chem (2007) 0.96
Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A. J Biol Chem (2009) 0.95
Ser(214) is crucial for substrate binding to serine proteases. J Biol Chem (2002) 0.92
Interaction of the factor XIII activation peptide with alpha -thrombin. Crystal structure of its enzyme-substrate analog complex. J Biol Chem (2000) 0.91
Stabilization of the E* form turns thrombin into an anticoagulant. J Biol Chem (2009) 0.91
Role of the A chain in thrombin function. Cell Mol Life Sci (2008) 0.91
Limited generation of activated protein C during infusion of the protein C activator thrombin analog W215A/E217A in primates. J Thromb Haemost (2006) 0.90
Selective loss of fibrinogen clotting in a loop-less thrombin. J Biol Chem (1997) 0.90
Residue Asp-189 controls both substrate binding and the monovalent cation specificity of thrombin. J Biol Chem (2003) 0.89
Engineering protease specificity made simple, but not simpler. Nat Chem Biol (2008) 0.82
Employing mutants to study thrombin residues responsible for factor XIII activation peptide recognition: a kinetic study. Biochemistry (2007) 0.81
Thromboprophylaxis and early antithrombotic therapy in patients with acute ischemic stroke and cerebral venous and sinus thrombosis. Eur J Med Res (2004) 0.76
Tipping the balance of blood coagulation. Nat Biotechnol (1997) 0.76
Thrombolytic therapy for acute ischemic stroke: 3 h and beyond. Expert Rev Neurother (2005) 0.76
Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci (2002) 1.96
Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist. Arterioscler Thromb Vasc Biol (2007) 1.80
Role of Na+ and K+ in enzyme function. Physiol Rev (2006) 1.80
Molecular dissection of Na+ binding to thrombin. J Biol Chem (2004) 1.72
The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood (2011) 1.71
Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma' chains. Blood (2005) 1.64
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem (2006) 1.58
Exposure of R169 controls protein C activation and autoactivation. Blood (2012) 1.52
Conformational selection or induced fit? A critical appraisal of the kinetic mechanism. Biochemistry (2012) 1.39
Structural identification of the pathway of long-range communication in an allosteric enzyme. Proc Natl Acad Sci U S A (2008) 1.31
Rapid kinetics of Na+ binding to thrombin. J Biol Chem (2006) 1.29
Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc Natl Acad Sci U S A (2007) 1.23
Conformational selection in trypsin-like proteases. Curr Opin Struct Biol (2012) 1.20
The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem (2002) 1.19
Evolution of peptidase diversity. J Biol Chem (2008) 1.16
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood (2007) 1.12
Crystal structure of thrombin in a self-inhibited conformation. J Biol Chem (2006) 1.11
The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. J Biol Chem (2004) 1.10
Thrombomodulin changes the molecular surface of interaction and the rate of complex formation between thrombin and protein C. J Biol Chem (2004) 1.08
Allostery in trypsin-like proteases suggests new therapeutic strategies. Trends Biotechnol (2011) 1.07
Redesigning the monovalent cation specificity of an enzyme. Proc Natl Acad Sci U S A (2003) 1.05
Conformational selection is a dominant mechanism of ligand binding. Biochemistry (2013) 1.05
Mechanism of Na(+) binding to thrombin resolved by ultra-rapid kinetics. Biophys Chem (2007) 1.01
Crystal structure of thrombin in complex with fibrinogen gamma' peptide. Biophys Chem (2006) 0.99
Crystallographic and kinetic evidence of allostery in a trypsin-like protease. Biochemistry (2011) 0.98
Mutant N143P reveals how Na+ activates thrombin. J Biol Chem (2009) 0.97
Crystal structures of prethrombin-2 reveal alternative conformations under identical solution conditions and the mechanism of zymogen activation. Biochemistry (2011) 0.97
Important role of the cys-191 cys-220 disulfide bond in thrombin function and allostery. J Biol Chem (2007) 0.96
A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem (2005) 0.96
Crystal structure of the anticoagulant slow form of thrombin. J Biol Chem (2002) 0.96
Crystal structure of prethrombin-1. Proc Natl Acad Sci U S A (2010) 0.96
Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1. J Biol Chem (2010) 0.96
Dissecting substrate recognition by thrombin using the inactive mutant S195A. Biophys Chem (2003) 0.96
Energetic and structural consequences of perturbing Gly-193 in the oxyanion hole of serine proteases. J Biol Chem (2005) 0.95
Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A. J Biol Chem (2009) 0.95
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. Stroke (2011) 0.94
The conformation of the activation peptide of protein C is influenced by Ca2+ and Na+ binding. J Biol Chem (2004) 0.93
Murine thrombin lacks Na+ activation but retains high catalytic activity. J Biol Chem (2006) 0.93
Autoactivation of thrombin precursors. J Biol Chem (2013) 0.92
Crystal structure of prothrombin reveals conformational flexibility and mechanism of activation. J Biol Chem (2013) 0.92
Ser(214) is crucial for substrate binding to serine proteases. J Biol Chem (2002) 0.92
Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem (2007) 0.92
Three-dimensional models of proteases involved in patterning of the Drosophila Embryo. Crucial role of predicted cation binding sites. J Biol Chem (2002) 0.92
Stabilization of the E* form turns thrombin into an anticoagulant. J Biol Chem (2009) 0.91
The thrombin epitope recognizing thrombomodulin is a highly cooperative hot spot in exosite I. J Biol Chem (2002) 0.90
Residue Asp-189 controls both substrate binding and the monovalent cation specificity of thrombin. J Biol Chem (2003) 0.89
Evidence of the E*-E equilibrium from rapid kinetics of Na+ binding to activated protein C and factor Xa. J Phys Chem B (2010) 0.89
Hirudin binding reveals key determinants of thrombin allostery. J Biol Chem (2005) 0.88
Rigidification of the autolysis loop enhances Na(+) binding to thrombin. Biophys Chem (2011) 0.88
High resolution crystal structures of free thrombin in the presence of K(+) reveal the molecular basis of monovalent cation selectivity and an inactive slow form. Biophys Chem (2006) 0.88
Conserved Ser residues, the shutter region, and speciation in serpin evolution. J Biol Chem (2003) 0.86
Thrombin functions through its RGD sequence in a non-canonical conformation. J Biol Chem (2005) 0.86
Histone H4 promotes prothrombin autoactivation. J Biol Chem (2013) 0.86
Substrate recognition drives the evolution of serine proteases. J Biol Chem (2002) 0.85
Structural basis of Na+ activation mimicry in murine thrombin. J Biol Chem (2007) 0.85
Structural basis of thrombin-protease-activated receptor interactions. IUBMB Life (2011) 0.84
Engineering protein allostery: 1.05 A resolution structure and enzymatic properties of a Na+-activated trypsin. J Mol Biol (2008) 0.83
Three-dimensional modeling of thrombin-fibrinogen interaction. J Biol Chem (2002) 0.83
Engineering protease specificity made simple, but not simpler. Nat Chem Biol (2008) 0.82
Conversion of trypsin into a Na(+)-activated enzyme. Biochemistry (2006) 0.82
Redesigning allosteric activation in an enzyme. Proc Natl Acad Sci U S A (2011) 0.82
Why Ser and not Thr brokers catalysis in the trypsin fold. Biochemistry (2015) 0.80
The role of Zn2+ on the structure and stability of murine adenosine deaminase. J Phys Chem B (2010) 0.79
Combinatorial enzyme design probes allostery and cooperativity in the trypsin fold. J Mol Biol (2010) 0.79
Is Na+ a coagulation factor? Thromb Haemost (2006) 0.79
Atherosclerosis: testing the water. Arterioscler Thromb Vasc Biol (2003) 0.78
Allosteric effects potentiating the release of the second fibrinopeptide A from fibrinogen by thrombin. J Biol Chem (2002) 0.78
Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis. Thromb Res (2011) 0.77
Crystal structure of the thrombin mutant D221A/D222K: the Asp222:Arg187 ion-pair stabilizes the fast form. Biophys Chem (2004) 0.76
Interaction between thrombin mutant W215A/E217A and direct thrombin inhibitor. Blood Coagul Fibrinolysis (2008) 0.76
Prothrombin structure: unanticipated features and opportunities. Expert Rev Proteomics (2014) 0.76
Introduction to mini-theme issue on "protease-activated receptor signaling". IUBMB Life (2011) 0.75
In vitro veritas: 90 years of biochemistry at Saint Louis University. Mo Med (2013) 0.75
Modifications of nuclear DNA and its regulatory proteins. Preface. Prog Mol Biol Transl Sci (2011) 0.75
Jeffries Wyman. Biogr Mem Natl Acad Sci (2003) 0.75